Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Yolk Sac Tumor: early-phase trial registry

4 of 7 indexed Yolk Sac Tumor trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Yolk Sac Tumor: 7 US clinical trials tracked, 4 recruiting.

Yolk Sac Tumor is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Baylor College of Medicine, running 4 of these trials.

Enrollment posture brief

Registry condition yolk-sac-tumor

OPEN 4 | RECR 57% | LATE 1 | EARLY 5 | RANK #2497 | SPON 4

Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)

ACL Tear71.4%ACL57.1%Yolk Sac Tumor (this)57%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Yolk Sac Tumor

Yolk Sac Tumor lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Yolk Sac Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Yolk Sac Tumor is recruiting above its size-band peers.

    4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Yolk Sac Tumor research.

    Baylor College of Medicine accounts for 4 of 7 trials (57.1%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Yolk Sac Tumor trials plan to enrol fewer than 100 people.

    Median target enrolment is 21 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.

  4. Yolk Sac Tumor research is mostly interventional.

    6 interventional and 1 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15Phase 31

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 3 1

Named interventions

Most-linked intervention names on Yolk Sac Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

AGAR T cells Genetic
1 trials
CATCH T cells Genetic
1 trials
pegylated G-CSF Drug
1 trials
ifosfamide Drug
1 trials
Germline DNA Samples Other
1 trials
Tumor Specimen Collection Other
1 trials
Blood Sample Collection Procedure
1 trials
CARE T cells Genetic
1 trials

US sites by state

Facility locations filed on Yolk Sac Tumor trials. A trial with sites in several states counts in each.

Texas 4 trials
Washington 1 trials
Minnesota 1 trials
Illinois 1 trials
Georgia 1 trials
Florida 1 trials
Delaware 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Yolk Sac Tumor page

7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Yolk Sac Tumor condition card totals 7 registered trials; most-linked intervention AGAR T cells; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.